NASDAQ:VRNA - VERONA PHARMA P/S Stock Price, Forecast & News

VERONA PHARMA P/S trades on the NASDAQ under the ticker symbol "VRNA."

VERONA PHARMA P/S is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for VERONA PHARMA P/S.

VERONA PHARMA P/S will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

3 analysts have issued twelve-month price objectives for VERONA PHARMA P/S's stock. Their forecasts range from $17.00 to $60.00. On average, they anticipate VERONA PHARMA P/S's stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 444.9% from the stock's current price. View Analyst Price Targets for VERONA PHARMA P/S.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VERONA PHARMA P/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VERONA PHARMA P/S.

Media headlines about VRNA stock have trended very positive on Sunday, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. VERONA PHARMA P/S earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for VERONA PHARMA P/S.

VERONA PHARMA P/S saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 84,300 shares, a decline of 51.0% from the January 15th total of 171,900 shares. Based on an average daily volume of 231,400 shares, the days-to-cover ratio is currently 0.4 days. Approximately 1.1% of the company's shares are sold short. View VERONA PHARMA P/S's Current Options Chain.

Some companies that are related to VERONA PHARMA P/S include Minerva Neurosciences (NERV), Evolus (EOLS), Spectrum Pharmaceuticals (SPPI), CytomX Therapeutics (CTMX), Wave Life Sciences (WVE), Concert Pharmaceuticals (CNCE), OptiNose (OPTN), Albireo Pharma (ALBO), AMAG Pharmaceuticals (AMAG), Osmotica Pharmaceuticals (OSMT), MannKind (MNKD), Aduro BioTech (ADRO), Syros Pharmaceuticals (SYRS), Evofem Biosciences (EVFM) and Lexicon Pharmaceuticals (LXRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other VERONA PHARMA P/S investors own include Ligand Pharmaceuticals (LGND), Novavax (NVAX), Sorrento Therapeutics (SRNE), Supernus Pharmaceuticals (SUPN), Teva Pharmaceutical Industries (TEVA), Cara Therapeutics (CARA), Galmed Pharmaceuticals (GLMD), SUMMIT THERAPEU/S (SMMT), Viking Therapeutics (VKTX) and CareDx (CDNA).

(VRNA) raised $61 million in an IPO on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

VERONA PHARMA P/S's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.62%), Renaissance Technologies LLC (0.09%) and UBS Group AG (0.08%).

VRNA stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., Renaissance Technologies LLC and UBS Group AG.

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VRNA stock can currently be purchased for approximately $6.79.

VERONA PHARMA P/S has a market capitalization of $89.42 million. The company earns $-26,560,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. VERONA PHARMA P/S employs 22 workers across the globe.View Additional Information About VERONA PHARMA P/S.

The official website for VERONA PHARMA P/S is http://www.veronapharma.com/.

VERONA PHARMA P/S's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]